Felipe José Silva Melo Cruz

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Maha Hussain, Bertrand Tombal, Fred Saad et al. · Journal of Clinical Oncology · 2023 · 215 citations · Full text

Medicine, Oncology, Pharmacology +17

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad, Egils Vjaters, Neal D. Shore et al. · Journal of Clinical Oncology · 2024 · 141 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim et al. · Journal of Clinical Oncology · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +16

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology · 2024 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17